Immunopotentiators in Modern Vaccines

by Virgil E.J.C. Schijns PhD (Editor), Derek T. O'Hagan PhD (Editor)

Overview

Immunopotentiators in Modern Vaccines provides an in-depth insight and overview of a number of most promising immunopotentiators in modern vaccines. In contrast to existing books on the subject it provides recent data on the critical mechanisms governing the activity of vaccine adjuvants and delivery systems. Knowledge of immunological pathways and scenarios of the cells and molecules involved is described and depicted in comprehensive illustrations. - Contributions from leading international authorities in the field - Well-illustrated, informative figures present the interactions between immunopotentiators and the host immune system - Each chapter lists advantages and potential hurdles for achieving a practical application for the specific immunopentiator

Product Details

ISBN-13:	9780080457215
Publisher:	Elsevier Science & Technology Books
Publication date:	12/19/2005
Sold by:	Barnes & Noble
Format:	eBook
Pages:	384
File size:	9 MB

About the Author

Dr. Virgil E.J.C. Schijns is special guest Professor in Cell Biology & Immunology group, Wageningen University, 6708 WD Wageningen, The Netherlands. Dr. Schijns received his PhD degree at Utrecht University in 1990. Recent professional appointments are Chief Scientific Officer at ERC in Belgium and The Netherlands, (2011 to present); Chief Technology Officer, Vice President at a small biotech spin-off from Utrecht University (2008 to 2011); Special Professor, Immune Intervention, Wageningen University and Research Center (2008 to present); Special Professor in Immunology and Virology at North Carolina State University (NCSU), Raleigh. Department of Population Health and Pathobiology (2002 to present) and Head of Department for Vaccine Technology and Immunology (VTI), AKZO NOBEL (1999 to 2008).
Dr. Derek T. O’Hagan is a formulation scientist and vaccine adjuvant expert with extensive industry experience. He served as Global Head of Vaccine Chemistry and Formulation Research at Novartis Vaccines before its acquisition by GSK. With a background in pharmacy from the UK, he has worked in vaccine delivery research since 1993, including academic roles at the University of Nottingham. Dr. O’Hagan has led research on adjuvants such as MF59, now licensed in flu vaccines in over 40 countries. He has authored over 140 research publications, 60+ patents, and numerous book chapters. Recognized for innovation, he received the Royal Pharmaceutical Society’s Conference Science Medal and the Controlled Release Society’s Young Investigator Award. His work focuses on adjuvant development, nucleic acid vaccines, and needle-free delivery systems, making him a leading figure in vaccine formulation science.

Table of Contents

Preface List of contributors Part I: Perspective on immunological mechanisms underlying adjuvant activity Chapter 1: Unraveling “the immunologist's dirty little secret†Part II: Host-derived immunopotentiators Chapter 2: Dendritic cells as targets and tools in vaccines Chapter 3: Host-derived molecules as adjuvants Part III: Natural and synthetic immunopotentiators Chapter 4: Innate immune mechanisms and the identification of immune potentiators as vaccine adjuvants Chapter 5: CpG oligodeoxynucleotides as vaccine adjuvants Chapter 6: Toll-like receptor 4 agonists as vaccine adjuvants Chapter 7: Immunomodulatory adjuvants from Quillaja saponaria Part IV: Particulate immunopotentiators and delivery systems Chapter 8: Microparticles as vaccine delivery systems Chapter 9: MF59: a safe and potent adjuvant for human use Chapter 10: Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt Chapter 11: Virosomes for vaccine delivery Chapter 12: The ISCOMATRIXâ"¢ adjuvant Chapter 13: Mineral adjuvants Part V: Mucosal/nonparenteral adjuvants Chapter 14: Mucosal adjuvants based on cholera toxin and E. coli heat-labile enterotoxin Chapter 15: Transcutaneous immunization using the heat-labile enterotoxin of E. coli as an adjuvant Part VI: Th-1/CTL adjuvants Chapter 16: T cell adjuvants and novel strategies for their identification Part VII: Adjuvants in noninfectious disease vaccines Chapter 17: Vaccination to treat noninfectious diseases: surveying the opportunities Part VIII: Clinical practice Chapter 18: Clinical evaluation of adjuvants Chapter 19: Regulatory considerations in the nonclinical safety assessment of adjuvanted preventive vaccines Index

What People are Saying About This

From the Publisher

Provides completely updated insights into the mechanism of action of modern immunopotentiators and their potential use in future vaccines